Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

kinase inhibitor

This page shows the latest kinase inhibitor news and features for those working in and with pharma, biotech and healthcare.

Rigel and Ultragenyx claim approvals for rare drugs

Rigel and Ultragenyx claim approvals for rare drugs

All’s well that ends well however, with the US regulator giving its blessing to the first-in-class oral spleen tyrosine kinase (SYK) inhibitor after a lengthy and often turbulent

Latest news

  • Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

    The EMA and FDA have started the clock ticking on their appraisals for dacomitinib, a pan-EGFR tyrosine kinase inhibitor, for the first-line treatment of patients with locally advanced or ... September. The study showed that dacomitinib improved median

  • NICE reverses its rejection of Eisai’s Lenvima NICE reverses its rejection of Eisai’s Lenvima

    The positive recommendation comes three years after the tyrosine kinase inhibitor achieved an initial EU licence from the European Medicines Agency (EMA).

  • FDA’s year-end approvals take annual tally to 46 FDA’s year-end approvals take annual tally to 46

    which as yet is the only fixed-dose SGLT2/DPP-4 inhibitor pairing on the US market. ... It has become the first and only BCR-ABL tyrosine kinase inhibitor (TKI) to include data about attempting treatment discontinuation in adult patients with

  • Sutent gets FDA approval for early use in kidney cancer Sutent gets FDA approval for early use in kidney cancer

    First launched in 2006, kinase inhibitor Sutent (sunitinib malate) is Pfizer’s second-biggest cancer drug, bringing in $805m in sales in the first nine months of 2017 but has started ... While most first-line therapies such as kinase drugs provide a

  • Sanofi licences Principia MS drug in $805m deal Sanofi licences Principia MS drug in $805m deal

    payment. The focus of the deal is PRN2246, a Bruton’s tyrosine kinase (BTK) inhibitor that is in phase I clinical development for a number of central nervous system diseases. ... The BTK inhibitor has been specifically designed to cross the blood-brain

More from news
Approximately 1 fully matching, plus 160 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Acquisition company - remaining 90%. 9, 000. Impact Biomedicines/ Celgene. Fedratinib, highly selective JAK2 kinase inhibitor for myelofibrosis (p3) and polycythemia vera. ... This acquisition brings tucatinib, an oral tyrosine kinase inhibitor that is

  • Accelerating innovation Accelerating innovation

    While the company waits to hear from the EMA, there is also work underway to explore the use of Ipsen’s tyrosine-kinase inhibitor (TKI) Cabometyx in combination with some of

  • Deal Watch September 2016 Deal Watch September 2016

    No financial terms were disclosed. Genentech signed an exclusive licence [global excluding South Korea] with Hanmi Pharmaceutical to develop and market HM95573, a pan-RAF inhibitor. ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective

  • Deal Watch June 2016 Deal Watch June 2016

    acquisition assets. 350. CrystalGenomics/ Aptose Biosciences. CG026806 inhibitor of Bruton's tyrosine kinase, FMS-like tyrosine kinase 3 and Aurora kinases (preclinical). † ... acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe.

  • Deal Watch May 2016 Deal Watch May 2016

    Paying a 55% premium at $99.25 per share, the acquisition brings crisaborole, a topical PDE4 inhibitor for mild to moderate atopic dermatitis (eczema) with estimated peak sales of $2bn. ... 282. Carna Biosciences/ ProNAi Therapeutics. Licence. $0.9m

More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Quick links

Infographics

Multimedia